Print this page
-
A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer.
Protocol: 032209Principal Investigator:
- Missak Haigentz MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lung -
A Phase IA/IB, Open Label, Multicenter, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors.
Protocol: 052212Principal Investigator:
- Sanjay Goel (Rutgers University)
Applicable Disease Sites: Any Site -
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab.
Protocol: 072213Principal Investigator:
- Sharon Li (Rutgers University)
Applicable Disease Sites: Liver -
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors.
Protocol: 052215Principal Investigator:
- Sanjay Goel (Rutgers University)
Applicable Disease Sites: Any Site -
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLAA*02:01-Positive Participants with Previously Treated Advanced Melanoma.
Protocol: 092203Principal Investigator:
- Sarah Weiss MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Melanoma, Skin -
A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma.
Protocol: 012207Principal Investigator:
- Andrew Evens M.D (Rutgers University)
Applicable Disease Sites: Any Site